Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK to acquire AZ Tika

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline plans to acquire Sweden's leading OTC analgesic treatment, Alvedon, as part of a deal to buy AZ Tika from AstraZeneca for 146 million U.K. pounds ($219 million), the U.K.-based firm announces Nov. 20. AZ Tika's portfolio also includes Minifom, for GI disorders, and the decongestants Nezeril and Nasin, all of which are sold predominantly in Sweden and the Nordic region. The product portfolio's net sales reached about $40.5 million in 2007





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts